VMI
HRTX icon

VHCP Management II’s Heron Therapeutics HRTX Stock Holding History

VHCP Management II’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-405,901
Closed -$5.32M – 21
2016
Q4 		$5.32M Hold
405,901
– – 2.55% 11
2016
Q3 		$6.99M Hold
405,901
– – 3.59% 8
2016
Q2 		$7.33M Hold
405,901
– – 4.42% 7
2016
Q1 		$7.71M Buy
+405,901
New +$8.01M 5.07% 7

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

VHCP Management II's HRTX Position: Q1 2017 in Review

VHCP Management II sold out of Heron Therapeutics (HRTX) in Q1 2017, closing a stake of 405,901 shares — an estimated $5.32M sold.

VHCP Management II first reported a position in HRTX in Q1 2016 and held it in 4 quarters. The position peaked at $7.71M in Q1 2016. 100 funds tracked by Wall St. Rank hold HRTX as of Q1 2017.

  • VHCP Management II reported no remaining Heron Therapeutics position as of Q1 2017 after selling out during the quarter.
  • VHCP Management II sold 405,901 Heron Therapeutics shares in Q1 2017, an estimated $5.32M.
  • VHCP Management II first reported a position in Heron Therapeutics in Q1 2016 and held it in 4 quarters.
  • VHCP Management II's Heron Therapeutics position peaked at $7.71M in Q1 2016.
  • 100 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2017.

Based on VHCP Management II's 13F filing for Q1 2017, filed 12 May 2017.